TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group Limited announced that its investigational new drug application for the radionuclide-drug conjugate TLX591, aimed at treating prostate cancer, has been accepted for an international Phase III clinical trial by China’s National Medical Products Administration. This development marks a significant advancement in the company’s nuclear medicine segment, which is focused on providing integrated diagnostic and therapeutic solutions for prostate cancer. The trial will evaluate TLX591’s efficacy and safety in combination with standard care for patients with metastatic castration-resistant prostate cancer. The innovative design of TLX591, which requires a shorter treatment cycle and offers safety advantages, positions it as a potential new standard in prostate cancer treatment, addressing clinical challenges associated with existing therapies.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a company incorporated in Bermuda, focusing on the development and commercialization of innovative nuclear medicine products. The company is engaged in the anti-tumor diagnosis and treatment industry, with a strong emphasis on radionuclide-drug conjugates for cancer treatment. It has a comprehensive strategic plan covering R&D, production, sales, and regulatory qualifications, and collaborates with international partners to advance its product pipeline.
Average Trading Volume: 9,759,360
Technical Sentiment Signal: Buy
Current Market Cap: HK$21.26B
See more data about 0512 stock on TipRanks’ Stock Analysis page.